A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

An Open-label Study of MabThera on Objective Overall Tumor Response in Treatment-naïve Patients With Non-bulky Follicular Non-Hodgkin's Lymphoma

This study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in treatment-naive patients with non-bulky follicular non-Hodgkin's lymphoma. The anticipated time on study treatment is 3 months.

Inclusion Criteria:

• Adult patients 18-75 years of age
• Newly diagnosed non-bulky follicular non-Hodgkin's lymphoma
• >/=1 measurable lesion
• No prior treatment (no corticosteroids or radiotherapy)

Exclusion Criteria:

• Transformed follicular lymphoma
• Cerebral or meningeal lymphomaotus localization
• Uncontrolled concurrent infection